Virus-like Particles for TEM Regulation and Antitumor Therapy

Area of Science:

• Biotechnology
• Nanomedicine
• Immunology

Background:

• Tumor development and metastasis are linked to the tumor microenvironment (TME).
• Conventional vector-restricted drugs face challenges in achieving long-term efficacy within the TME for cancer immunotherapy.
• Virus-like particles (VLPs) are emerging as promising nanocarriers for therapeutic applications.

Purpose of the Study:

• To review the design principles of virus-like particles (VLPs) as nanocarriers.
• To explore the advancements in utilizing VLPs for regulating the tumor microenvironment (TME) in cancer immunotherapy.

Main Methods:

• Review of scientific literature on VLP design and TME targeting strategies.
• Analysis of VLP properties, including size, self-assembly, and immunogenicity.
• Examination of VLP surface modification techniques for enhanced TME interaction.

Main Results:

• VLPs, self-assembled from viral proteins, range from 20-200 nm and can induce humoral immunity.
• VLP surfaces can be genetically or chemically modified for targeted delivery to the TME.
• VLPs demonstrate potential for overcoming drug delivery limitations in cancer immunotherapy.

Conclusions:

• Virus-like particles (VLPs) present a versatile platform for nanocarrier development in cancer immunotherapy.
• Targeted VLP delivery to the TME is a key strategy for enhancing therapeutic outcomes.
• Further research into VLP design and functionalization is crucial for advancing cancer treatment.